The National Institute for Health and Care Excellence (NICE) is working with the Canadian Agency for Drugs and Technology in Health (CADTH) to offer parallel scientific advice to the life sciences industry.
The collaboration aims is to help companies prepare for future health technology assessments by answering their questions and providing key insight on their clinical and health economic development plans.
The parallel advice service will feature a joint summary, highlighting areas of synergy from the two agencies, and two separate advice reports from NICE and CADTH.
The scientific advice will also assist companies in developing evidence that demonstrates the value of a technology by providing detailed feedback on their clinical and economic evidence generation plans, using expert opinion from a range of contributors including clinicians, health economists and patient representatives.
Jeanette Kusel, director of NICE Scientific Advice said: “we recognise the inherent difficulties faced by developers in designing clinical trial programmes that meet the precise requirements of multiple international markets.
“This new collaboration with CADTH uses the synergies between the English and Canadian systems and provides companies with comprehensive and practical advice from both countries through a single, streamlined process.”
